Haematology 2018

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin A et al J Clin Oncol. 2016 Aug 10;34(23):2698-704.

DLBCL • N=11; ORR 36% (n=4), 2 CR, and 2 PR. •

Median follow-up duration of 22.7 weeks, response durations were 6 and 77.3+ weeks for CR patients and 12.1+ and 22.1 weeks for PR patents. FL • ORR 40% (n=4), including 1 CR and 3 PR. • Median follow-up duration of 91.4 weeks, individual response durations were 81.6+ weeks for the patient with CR and 27.1+, 28.1+, and 32.1+ weeks for the patients with PR.